# A Study to Evaluate the Efficacy and Safety of AD-224

> **NCT06291207** · PHASE3 · RECRUITING · sponsor: **Addpharma Inc.** · enrollment: 252 (estimated)

## Conditions studied

- Hypertension,Essential

## Interventions

- **DRUG:** AD-224A
- **DRUG:** AD-224B
- **DRUG:** AD-224C
- **DRUG:** Placebo of AD-224A
- **DRUG:** Placebo of AD-224B
- **DRUG:** Placebo of AD-224C

## Key facts

- **NCT ID:** NCT06291207
- **Lead sponsor:** Addpharma Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-04-15
- **Primary completion:** 2025-07
- **Final completion:** 2025-07
- **Target enrollment:** 252 (ESTIMATED)
- **Last updated:** 2025-02-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06291207

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06291207, "A Study to Evaluate the Efficacy and Safety of AD-224". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT06291207. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*